Description
The ProbeSeq Human Epidermal Growth Factor Receptor 2 (HER2 / ERBB2) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to HER2, a transmembrane receptor tyrosine kinase involved in cellular growth and proliferation signaling. This nanobody supports research-use diagnostic assay development, oncology biomarker detection, and advanced biosensor integration.
HER2 is a clinically validated biomarker widely used in breast cancer classification, therapeutic response monitoring, and tumor progression assessment. Overexpression or amplification of HER2 is associated with aggressive tumor phenotypes and targeted therapy selection. Sensitive and specific detection of HER2 is critical for oncology research, liquid biopsy studies, and development of rapid point-of-care cancer diagnostics.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and high structural stability. Compared with conventional antibodies, nanobodies offer improved thermal stability, enhanced surface immobilization efficiency, and reduced steric hindrance, making them highly suitable for electrochemical biosensors, microfluidic platforms, and high-sensitivity diagnostic systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cell lysates, extracellular vesicles, and buffered biological samples following assay optimization.
What’s Included
Recombinant anti-HER2 single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request.
Target Strategy
Engineered for high binding specificity to HER2 extracellular domain epitopes
Minimal cross-reactivity with related receptor tyrosine kinases
Stable binding under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request.
Performance Orientation
Electrochemical biosensors
Immunoassay development
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care oncology diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request.
Applications
Breast cancer biomarker detection research
Oncology diagnostic development
Cancer progression monitoring studies
Liquid biopsy and extracellular vesicle research
Immunoassay and biosensor development
Microfluidic and point-of-care platform integration
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
